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Abstract 
Objective and Background: Extracts from pine tree bark containing a variety of 
flavonoids have been used in traditional medicine. Pycnogenol is a proprietary bark 
extract of the French maritime pine tree (Pinus pinaster ssp. atlantica) that exerts 
antioxidative, anti-inflammatory and anti-platelet effects. However, the effects of 
Pycnogenol on endothelial dysfunction, a precursor of atherosclerosis and 
cardiovascular events remain still elusive. 
Methods and Results: 23 patients with coronary artery disease (CAD) were 
completed this randomized, double-blind, placebo-controlled crossover study. 
Patients received Pycnogenol (200mg/d) for 8 weeks followed by placebo or vice 
versa on top of standard cardiovascular therapy. Between the 2 treatment periods a 
2-week washout period was scheduled. At baseline and after each treatment period, 
endothelial function, non-invasively assessed by flow-mediated dilatation (FMD) of 
the brachial artery using high-resolution ultrasound, biomarkers of oxidative stress 
and inflammation, platelet adhesion and 24-hour blood pressure monitoring were 
evaluated. In CAD patients FMD improved from 5.3±2.6 to 7.0±3.1 (p<0.0001) by 
Pycnogenol treatment; while no change was observed with placebo (5.4±2.4 to 
4.7±2.0; p=0.051). This difference between study groups was significant (estimated 
treatment effect 2.75; 95%CI 1.75-3.75, p<0.0001). 15-F2t-Isoprostane, an index of 
oxidative stress, significantly decreased from 0.71±0.09 to 0.66±0.13 after 
Pycnogenol treatment, while no change was observed in the placebo group (mean 
difference 0.06pg/ml with an associated 95% confidence interval [0.01, 0.11], 
p=0.012). Inflammation markers, platelet adhesion and blood pressure did not 
change after treatment with Pycnogenol or placebo. 
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Conclusions: This study provides the first evidence that the antioxidant Pycnogenol 
improves endothelial function in patients with coronary artery disease by reducing 
oxidative stress. 
 
Keywords: Pycnogenol; coronary artery disease; clinical trial; endothelial function; 
oxidative stress 
Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00641758 
Pycnogenol improves endothelial function 
Page 4 of 32 
Introduction 
Extracts from pine tree bark have been used in traditional medicine. Pycnogenol is a 
bark extract of the French maritime pine tree (Pinus pinaster ssp. atlantica). The 
extract is prepared using a standardized procedure that includes an extraction of 
fresh pine bark with ethanol and water to the requirements published by the United 
States Pharmacopoeia (USP).1 The resulting product is a mixture of flavonoids as 
monomers, i.e. catechin and taxifolin, and condensed polymers (85%), as well as 
dodeoameric flavonols, designated as procyanidins, differing in structure and chain 
length. Procyanidins are biopolymers composed of catechin and epicatechin, widely 
distributed in the plant kingdom. Many edible fruits contain procyanidins, for example 
apples, berries, peanuts and grapes. Additionally, the extract contains phenolic acids 
as gallic, caffeic, and ferulic acid as minor constituents. Pycnogenol also contains 
glycosylation products, i.e., sugar derivatives of phenolcarbonic acids and taxifolin.2 
These molecules have antioxidant properties and may act as modulators of 
metabolic enzymes and other cellular functions.2 
In a pharmacokinetic study healthy volunteers ingested a single dose of 300 mg and 
repeated doses of 200 mg Pycnogenol.3 In blood samples catechin, taxifolin, ferulic 
acid, caffeic acid and the metabolite 5-(3’,4’-dihydroxyphenyl)-g-valerolactone (M1) 
were detected in concentrations up to 100 ng/mL. While the first four compounds are 
genuinely present in the maritime pine bark extract the metabolite M1 is formed in 
vivo from catechin polymers by gut microbiota.4, 5 This metabolite had been 
previously also found in urine samples after Pycnogenol intake.6 Additionally to these 
known constituents and metabolite ten yet unknown compounds were detected in 
human plasma samples.7 
The effects of the identified compounds have been investigated in vitro with the 
metabolite M1 revealing the highest activity. On a µg/mL basis M1 was more potent 
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than the original maritime pine bark extract in inhibiting the activity of matrix 
metalloproteinases (MMP) 1, 2 and 9.3 M1 was also about twice as potent as 
hydrocortisone in inhibiting the release of MMP-9 from freshly isolated human 
monocytes after stimulation with bacterial lipopolysaccharide (LPS). Thus, it appears 
very likely that M1 plays a major role in mediating the biological effects of 
Pycnogenol. 
However, it cannot be excluded that other yet unknown components or metabolites of 
Pycnogenol also contribute to its biologic activity. Plasma samples of volunteers who 
ingested Pycnogenol contained bioactive compounds which in addition to the 
inhibition of MMP-9 release statistically significantly inhibited NF-kB activation8 as 
well as cyclooxygenase (COX) 1 and 2 activity.9 
Pycnogenol has been shown to exert anti-inflammatory effects and to inhibit platelet 
aggregation, both risk factors for cardiovascular disease.2 In vitro, Pycnogenol 
prolonged the ascorbate radical lifetime to the greatest extent by regenerating 
ascorbic acid.10 Similarly, Pycnogenol inhibits LDL peroxidation, lipid peroxidation in 
phospholipid liposomes,2 and lipid peroxidation caused by t-butylhydroperoxide. 
Furthermore, Pycnogenol has antioxidant activity.10 Finally, in isolated blood vessels, 
Pycnogenol inhibits vasoconstriction caused by adrenalin via the production of nitric 
oxide.11 The present study was designed to evaluate the effect of Pycnogenol on 
endothelial function in patients with coronary artery disease (CAD). 
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Methods 
Study population 
Patients with CAD, documented by coronary angiography, nuclear imaging or a 
positive stress test, on stable cardiovascular medication for at least one month and 
≥18 years of age, who gave written informed consent, were recruited at the Clinic of 
Cardiology, Cardiovascular Center, University Hospital Zurich, Switzerland. 
Exclusion criteria were acute myocardial infarction, unstable angina, stroke, or 
coronary intervention / revascularization procedure within three months prior to study 
entry; uncontrolled symptomatic congestive heart failure (New York Heart 
Association functional class >II) in the last 4 weeks prior to study entry; smoking, 
alcohol or illicit substance abuse; uncontrolled blood pressure despite adequate 
therapy (≥160/100mmHg); symptomatic hypotension; ventricular tachyarrhythmias; 
any cardiomyopathy, untreated thyroid dysfunction or adrenal insufficiency; renal 
failure (creatinine clearance using the MDRD-formula12 < 50 ml/min); liver disease; 
chronic use of long-acting nitrates; oral or intravenous steroid therapy; insulin-
dependent diabetes mellitus; anaemia (Hb <10 g/dl); known hypersensitivity to 
Pycnogenol; systemic inflammatory diseases (e.g. rheumatoid arthritis, Crohn's 
disease); known human immunodeficiency virus (HIV) infection or active virus – 
hepatitis; pregnancy or breast-feeding, women with childbearing potential without 
adequate contraception; malignancy (unless healed or in remission >5 years); 
recipient of any major organ transplant (e.g. lung, liver, heart) or renal replacement 
therapy and the participation in another study within the last month. 
 
Study design and protocol 
In this single-centre, prospective, randomized, double - blind, placebo - controlled 
study in cross over fashion we analyzed the impact Pycnogenol on endothelium-
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dependent and -independent vasodilatation in patients with stable CAD receiving 
optimal standard therapy. Prespecified secondary endpoints were change in high 
sensitive CRP and CD-40 Ligand, change in total antioxidative capacity, oxidized 
LDL and 8-isoprostanes, change in ambulatory blood pressure (ABP) and change in 
shear-stress dependent platelet function. The protocol was approved by the 
Institutional Review Board (Ethics Committee of the Canton Zurich) and the Swiss 
Agency for Therapeutic Products (Swissmedic, Bern, Switzerland). The study was 
registered at ClinicalTrials.gov (Identifier: NCT00641758). 
After screening and recruiting, the patients were randomly assigned into two groups. 
For randomization an unpredictable allocation sequence was provided by external 
institutions (InterCorNet Zurich, Switzerland), which were responsible for the blinding 
and labelling of the drugs. The study drug and placebo were prepared in identical 
capsules to ensure uniform appearance of both formulations by the manufacturer 
Horphag Research (UK) Ltd, London, United Kingdom. All investigators including the 
ultrasonographers were unaware of the allocation procedure at any time. The 
patients were randomized to receive either Pycnogenol 200mg/day or matching 
placebo in the first part or vice versa in the second part with a washout period of two 
weeks in-between. 
At each visit (baseline and after 8, 10, and 18 weeks) endothelial function and ABP 
were measured, blood samples were drawn, the clinical status assessed and 
adverse events recorded. At each visit a safety analysis was performed including 
assessment of electrolytes, of liver and kidney function, as well as a white and red 
blood cell count. Pregnancy testing in women with childbearing potential was 
performed only at the first visit. The patients were advised not to take their usual 
drugs in the morning of the examination day (all examinations and measurements 
were performed in the morning), moreover, the medical therapy was unchanged 
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throughout the study. Blood samples and the evaluation of flow-mediated dilatation 
were performed before the patients took their medications. The regular medications 
and the study drug were taken thereafter and before the 24-hour ABPM was placed. 
 
Endothelium-dependent and -independent vasodilatation 
Flow-mediated dilatation (FMD) was performed according to the current guidelines13, 
14 and as previously described.15 In brief, a B-mode high-resolution ultrasound scan 
of the left brachial artery was obtained by highly trained and experienced 
sonographers in a longitudinal section between 2 and 10 cm above the elbow, using 
a high-resolution 10 MHz linear array transducer and a high-resolution ultrasound 
system Siemens X300 (Siemens Switzerland AG, Zurich, Switzerland). The analogue 
video signal was acquired with a video processing system that computed the artery 
diameter in real-time (FMD Studio16, a system for real-time measurement, Institute of 
Clinical Physiology, Pisa, Italy). The high reproducibility of the method has been 
demonstrated recently.17, 18 Baseline vessel size was considered as the mean of the 
measures obtained during the first minute. FMD was calculated as the maximal 
percent increase in diameter above baseline. Endothelium-independent dilatation 
was measured after sublingual glycerol trinitrate (GTN; 0.4mg, Nitrolingual Spray, 
Pohl-Boskamp, Hohenlockstedt, Germany) application by recording arterial diameter 
continuously for at least six minutes. The response to GTN is calculated as the 
maximum percent increase in vessel size above the baseline. The reproducibility of 
our laboratory was previously published.15 
 
Special laboratory analysis 
Oxidative stress markers: 8-epi-PGF2alpha (15-F2t-Isoprostane) was measured in 
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the plasma with an 8-Isoprostane Enzyme Immunoassay (8-isoprostane Express EIA 
Kit, Cayman Chemicals, Ann Arbor, MI, USA; intra-assay CV 7.2%, inter-assay CV 
15.5%). 
High Sensitivity C-reactive protein (hs-CRP): A high sensitive immunoluminometric 
assay (Imulite 2002, DCP, Los Angeles USA) was used to measure hsCRP levels as 
described by Wood et al.19 
Soluble Intercellular Adhesion Molecule-1 (sICAM-1), soluble Vascular Cell Adhesion 
Molecule-1 (sVCAM-1), soluble CD40 Ligand (sCD40L), oxidized LDL (oxLDL): 
EDTA plasma was drawn from each patient and immediately frozen at -70°C. Plasma 
samples were thawed only once for aliquotation before they were subjected to 
analyses. Quantitative detection of soluble Intercellular Adhesion Molecule-1 (sICAM-
1), soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), soluble CD40 Ligand 
(sCD40L) (all Bender Med Systems, Vienna, Austria), oxidized LDL (oxLDL) 
(Immundiagnostik, Bernsheim, Germany) and of Lipoprotein-associated 
phospholipase A2 (Lp-PLA2) (Uscn Life Sciences Inc., Wuhan, China) was performed 
using enzyme-linked immunosorbent assays (ELISA) according to the manufacturer’s 
instructions. Briefly, pre-coated microwell plates absorbed with specific capture 
antibodies directed against the respective molecule were washed thoroughly with the 
washing buffers provided.  Plasma samples were diluted where indicated and applied 
in duplicates before a 1 to 2 hour incubation at room temperature. Detection of the 
target molecules was performed using an HRP-conjugated detection antibody 
specific for the respective molecule, and visualized during a colour-giving reaction 
using the provided TMB substrate solution. Absorption was measured at 450nm and 
values were normalized to the respective internal standards supplied by the 
manufacturer. 
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Total antioxidant capacity: Total antioxidant capacity of plasma was measured using 
the total antioxidant capacity kit (Abcam, Cambridge, UK) according to the 
manufacturer’s instructions. Briefly, plasma was allowed to reduce Cu++ for 1.5 hours 
at room temperature. Reduced Cu+ was chelated with a colorimetric probe and 
absorbance was measured at 570nm. Results were expressed as trolox equivalent 
according to a trolox standard curve. 
Endothelin-1 (ET-1): The ET-1 sandwich ELISA-system from Assay Designs (Ann 
Arbor, MI, USA) was used according to the manufacturer’s instructions to measure 
ET-1 protein concentrations in EDTA plasma samples. Briefly, 500µL of each plasma 
sample was extracted with 650µL extraction solvent (acetone: 1 N HCl: water 
(40:1:5)) and dried under nitrogen streaming. Reconstituted in 120µL assay buffer 
samples were employed for testing. The sensitivity of the assay was determined to 
be 0.41pg/mL, the intra-assay coefficients of variation were 6.7% at 35.9pg/mL, 8.9% 
at 2.3pg/mL, and 8.8% at 1.1pg/mL; cross reactivity with human Big ET-1, ET-2 and 
ET-3 was low (human Big ET-1 <0.1 %, ET-2 21%, ET-3 3.6%). 
Asymmetric dimethylarginine (ADMA): ADMA concentration was measured from 
plasma samples by a competitive ELISA-system including an acylation step as pre-
treatment (DLD Diagnostika GmbH, Hamburg, Germany), with a standard range from 
0.1-5.0µmol/L. 20µL of each plasma sample were employed for testing. The 
detection limit of the system was 0.05 µmol/L. As described previously,20 the 
intraassay coefficients of variation were 5.7% at 0.66µmol/L and 6.4% at 1.01µmol/L; 
the interassay coefficient of variation ranged from 8.3% to 10.3%. Cross-reactivity 
with arginine and other methylarginines was low (arginine <0.02%; NG-monomethyl-
L-arginine 1.0%; symmetric dimethylarginine 1.2%). The correlation coefficients with 
liquid chromatography–mass spectrometry and gas chromatography–mass 
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spectrometry were high (0.991; 0.984), with a good linearity between 0.1 and 
5.0mol/L. 
Symmetric dimethylarginine (SDMA): SDMA was measured from serum samples by 
a competitive ELISA-system including an acylation step as pre-treatment (DLD 
Diagnostika GmbH, Hamburg, Germany) with a standard range from 0.08-3.0µmol/L. 
20µL of each plasma sample were employed for testing. The detection limit of the 
system was 0.05 µmol/L. The intraassay coefficients of variation were 5.7% at 
0.52µmol/L, 6.1% at 0.75µmol/L and 4.7% at 1.72µmol/L; cross-reactivity with 
arginine and other methylarginines were low (arginine <0.01%; NG-monomethyl-L-
arginine 0.70%; asymmetric dimethylarginine 0.44%). 
 
Ambulatory blood pressure measurement 
ABP measurements were obtained over 24 hours using the “Tracker NIBP 2” 
(Delmar, Del Mar Reynolds Medical, Hertford, UK) before and after the active 
treatment phase according to recent guidelines.21 Patients were asked to keep their 
arm calm while the cuff was inflating and to avoid excessive physical exertion during 
monitoring. The monitors were programmed to take readings every 15 minutes 
during daytime and every 30 minutes during nighttime. 
 
Shear Stress–dependent platelet function 
Shear stress–dependent platelet function was assessed with a cone and platelet 
analyzer as described previously.15, 22 
 
Statistical analysis 
The primary endpoint was the change in FMD after eight weeks of treatment with 
Pycnogenol compared to placebo. Based on previous studies,23 the estimated 
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sample size for this study is 25 (to show a difference of 1.3% in FMD when the 
standard deviation of 1.5%, giving 5% two-sided significance level and 85% power 
when using a t-test). Analysis was performed using Wilcoxon Mann-Whitney U-tests 
(to account for possible non-normality of the endpoints), using methods discussed by 
Senn.24 That is, we considered two distinct groups of patients: Group 1 who received 
Pycnogenol followed by placebo, and Group 2 who received placebo followed by 
Pycnogenol. Within each group, data are summarized by examining within patients 
changes between Periods 1 and 2 (for Group 1, this is the change from baseline 
while on placebo minus the change in baseline while on Pycnogenol; for Group 2, the 
change from baseline while on Pycnogenol minus the change in baseline while on 
placebo). These unpaired change scores are then analyzed using an unpaired 
Wilcoxon Mann-Whitney U-Test, as proposed by Hill and Armitage25, and later 
discussed by Senn.24 Statistical tests were preformed two-sided. The effect of 
Pycnogenol is estimated as the average of the two group-specific mean change 
scores. The period effect is estimated using the difference of the two group-specific 
mean change scores (divided by 2). The carry-over effect was excluded using an 
unpaired Wilcoxon test of within patient change from baseline including only the first 
period of treatment. A Bonferroni-Holm26 correction was made if necessary. For the 
“responder analysis”, patients were divided evenly into groups based on their FMD to 
Pycnogenol and placebo. Those with better responses were considered 
“responders”, the others, “non-responders”. The analyses for C-reactive protein and 
15-F2t-Isoprostane were then performed again separately for the 2 groups. Results 
are presented as mean ± SD or SEM as described. Analysis of the primary end-point 
was performed in the R programming language (R Development Core Team, 2009). 
The statistical software package SPSS 17 (SPSS Inc., Chicago, IL, USA) was used 
Pycnogenol improves endothelial function 
Page 13 of 32 
to evaluate difference in the clinical characteristics. Statistical significance was 
accepted at p<0.05. 
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Results 
Study population 
A total of 28 patients were enrolled, 5 patients discontinued the study prematurely, 3 
patients withdrew consent and 2 patient were excluded for adverse events: On 
patient in the Pycnogenol group was hospitalised for acute decompensated heart 
failure; one patient in the placebo group was excluded after development of an 
itching rash. Therefore, 23 patients (19 males and 4 females) with a mean age of 
63.1±7.1 years (range: 49-73 years) and a body mass index of 27.3±3.3 kg/m2 
completed the study protocol and were included into the analysis. Mean left 
ventricular ejection fraction was 62±10%. With the included 23 patients, the statistical 
power of 80%, is sufficient to detect differences of 1.3% in FMD between the two 
treatments. All patients had stable coronary artery disease, 11 patients with 1-vessel 
disease, 1 patient with 2-vessel disease and 11 patients with 3-vessel disease. Mean 
left ventricular ejection fraction was 62±10% in these patients.  
 
Effect of Pycnogenol on endothelium-dependent and -independent 
vasodilatation 
After 8 weeks treatment with Pycnogenol, FMD increased from 5.3±2.6% to 
7.0±3.1%, while it remained unchanged in the placebo group (5.4±2.4% to 4.7±2.0%; 
see Table 1 and Figure 1). The estimated effect of Pycnogenol on FMD was an 
increase of 2.75 compared to placebo (mean difference 2.75 with an associated 95% 
confidence interval [1.75, 3.74], p<0.0001), a statistically significant treatment effect. 
The period effect for this endpoint was estimated to be -0.32 (95% confidence 
interval [-1.31, 0.68], p=0.51), and therefore, not statistically significant. The 
endothelium-independent vasodilatation induced by GTN remained unchanged 
before and after treatment with Pycnogenol (Table 1). 
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Effect of Pycnogenol on ambulatory blood pressure 
Systolic and diastolic ambulatory blood pressure remained unchanged before and 
after treatment with Pycnogenol (Table 2). The estimated effect of Pycnogenol on 
systolic blood pressure was an increase of 1.17mmHg compared with placebo (mean 
difference 1.17mmHg with associated 95% confidence interval [-4.71, 7.04], p=0.68), 
a statistically non significant treatment effect. The estimated effect of Pycnogenol on 
diastolic blood pressure was an increase of 0.06mmHg compared with placebo 
(mean difference 0.06 mmHg with associated 95% confidence interval [-3.26, 3.37], p 
= 0.97), a statistically non significant treatment effect. 
 
Effect of Pycnogenol on oxidative stress 
15-F2t-Isoprostane was reduced significantly after 8 weeks treatment with 
Pycnogenol compared to baseline and placebo (Table 2 and Figure 2). The 
estimated effect of Pycnogenol on 15-F2t-Isoprostane was a decrease of 0.06pg/ml 
compared with placebo (mean difference 0.06pg/ml with an associated 95% 
confidence interval [0.01, 0.11], p=0.012), a statistically significant treatment effect. 
This effect was even more pronounced, when the patients “responders” and “non-
responders” were analysed. The estimated effect of Pycnogenol on 15-F2t-
Isoprostane (Responders) was a decrease of 0.1 compared with placebo (mean 
difference 0.1 with associated 95% confidence interval [0.00, 0.20], p = 0.045), a 
statistically significant treatment effect, while no change was observed in the “non-
responders”. The estimated effect of Pycnogenol on 15-F2t-Isoprostane (Non-
Responders) was an increase of 0.04 compared with placebo (mean difference 0.04 
with associated 95% confidence interval [-0.02, 0.10], p = 0.15), which was not 
statistically significant. 
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Effect of Pycnogenol on markers of inflammation 
The estimated effect of Pycnogenol on C-reactive protein was an increase of 
2.18mg/l compared with placebo (mean difference 2.18mg/l with associated 95% 
confidence interval [-3.35, 7.71], p=0.42), a statistically non significant treatment 
effect. Moreover, all of the following parameters remained unchanged before and 
after treatment with Pycnogenol or placebo (Table 2): Total antioxidant capacity 
(mean difference -0.19µM with associated 95% confidence interval [-2.20, 1.83], 
p=0.85), sVCAM (mean difference -20.44ng/ml with associated 95% confidence 
interval [-128.88, 88.00], p=0.7), sICAM (mean difference -67.38ng/ml with 
associated 95% confidence interval [-141.83, 7.07], p=0.073), sCD40-ligand (mean 
difference 0.02ng/ml with associated 95% confidence interval [-0.21, 0.25], p=0.85) 
and OxLDL (mean difference -2.56ng/ml with associated 95% confidence interval [-
18.59, 13.47], p=0.74), Lp-PLA2 (mean difference 74.83ng/ml with associated 95% 
confidence interval [-46.10, 195.76], p = 0.21). 
 
Effect of Pycnogenol on SDMA, ADMA and Endothelin-1 
The estimated effect of Pycnogenol on SDMA was a decrease of 0.06µM compared 
with placebo (mean difference -0.06µM with associated 95% confidence interval [-
0.16, 0.04], p=0.23), a statistically non significant treatment effect. The estimated 
effect of Pycnogenol on ADMA was a decrease of 0.05µM compared with placebo 
(mean difference -0.05 with associated 95% confidence interval [-0.12, 0.03], 
p=0.19). Though 57% of the patients receiving Pycnogenol and only 30% of the 
patients taking placebo revealed lower ADMA concentrations after the respective 
treatment period the effect was not statistically significantly different (Table 2). 
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The mean endothelin-1 concentrations of the participants were throughout at the 
lower limit of the reported physiological range between 1.10-2.70ng/l27 and no 
statistically significant treatment effect was observed (Table 2). 
 
Effect of Pycnogenol on shear-stress dependent platelet function 
Shear-stress dependent platelet function did not change after treatment with 
Pycnogenol (Table 2). The estimated effect of Pycnogenol on area fraction was a 
decrease of 0.22 compared with placebo (mean difference -0.22 with associated 95% 
confidence interval [-1.85, 1.42], p=0.78), a statistically non significant treatment 
effect. 
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Discussion 
This study demonstrates an improvement of endothelial function after 8 weeks 
treatment with the flavonoid extract Pycnogenol at a dose of 200mg QD as compared 
to placebo in patients with stable coronary artery disease.  
The balance between endothelial function and dysfunction plays an important role in 
the initiation and progression of atherosclerosis, and in the transition from a stable to 
an unstable disease state.28 As such the evaluation of endothelial function has 
emerged as an important endpoint in cardiovascular research. A recent meta-
analysis suggests that an impairment of brachial FMD is strongly associated with the 
occurrence of future cardiovascular events.29 Therefore, preservation or recovery of 
endothelial function is an important therapeutic aim in the prevention of 
arteriosclerosis and its clinical complications such as myocardial infarction and 
stroke. The improvement of endothelial function in our study was associated with a 
reduction in 8-isoprostanes, a maker for oxidative stress, but not with components of 
the L-arginine metabolism or markers of inflammation, indicating that antioxidant 
properties of the compound appear to be involved.  
An improvement of endothelial function has been demonstrated by Nishioka et al.30 in 
a randomized, double-blind, placebo-controlled study, including 16 healthy young 
man who were randomized to receive either Pycnogenol (180mg/d) or placebo for 2 
weeks. The investigators measured forearm blood flow (FBF) using strain-gauge 
plethysmography. They found an augmented FBF response to acethycholine (ACh) 
in the Pycnogenol group, while no augmentation was seen in the placebo group. 
However, sodium-nitroprusside (SNP) response was similar in both treatment groups 
and the administration of N(G)-monomethyl-L-arginine, a known NO synthase 
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inhibitor, abolished the Pycnogeol-induced augmentation to FBF response to ACh, 
suggesting an endothelium-dependent vasodilatation by increased NO production. 
Several lines of evidence suggest that oxidative stress may promote endothelial 
dysfunction through different mechanisms.31 First, diverse reactive oxygen species 
(ROS) are produced at increased levels within the vessel wall and they individually or 
in combination interfere with the function of endothelial and vascular smooth muscle 
cells.32 The family of ROS includes highly bioactive, short-living molecules that are 
derived from reduction of molecular oxygen. Multiple enzyme systems use different 
substrates as sources of electrons to produce a variety of ROS, the most important of 
which are nitric oxide (NO), superoxide (O2-), hydrogen peroxide (H2O2) and 
peroxynitrite (ONOO-). Many enzyme systems, including NAD(P)H oxidase, xanthine 
oxidase and uncoupled nitric oxide synthase (NOS) among others, contribute to 
production as well as to degradation of ROS.33 ONOO- is an important mediator of 
lipid peroxidation and protein nitration, including oxidation of low density lipoprotein 
(LDL), which has potent proatherogenic effects.32 NO is a crucial mediator of 
endothelium-dependent vasodilatation and also plays a role in platelet aggregation 
and in maintaining the balance between smooth muscle cell growth and 
differentiation.34 NO is rapidly inactivated by O2- to form ONOO-, a known mechanism 
of endothelial dysfunction. 
The short half-life of ROS makes them ideal signalling molecules, but it also 
confounds their measurement in complex biological systems, particularly in humans 
in vivo.32 On the other hand, F2-isoprostanes are associated with oxidative stress 
and are reliable markers of in vivo lipid peroxidation.35 Isoprostanes (iPs) are a family 
of prostaglandin (PG)-like compounds formed non-enzimatically through free radical 
catalysed attack on esterified arachidonate followed by enzymatic release from 
cellular or lipoprotein phospholipids.32 The measurement of F2-isoprostanes (F2-iPs), 
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containing F-type ring analogous to prostaglandin (PG)F2α, provides a reliable tool for 
identifying populations with enhanced rates of lipid peroxidation.32 In addition to their 
potential usefulness as indexes of oxidative stress in vivo, 8-iso-PGF2α is a 
vasoconstrictor and modulates platelet activation in response to other agonists.32 
Interestingly, in our study, 8-iso-PGF2α plasma levels decreased significantly by 
6.43±16.3% after therapy with Pycnogenol (p=0.012) as compared to placebo 
(increase of 4.54±11.1%). Moreover, the pronounced improvement of endothelial 
function after 8 weeks of treatment with Pycnogenol in the “responder” group was 
paralleled by an significant decrease in 15-F2t-Isoprostane, while in patients in the 
“non-responder” group no significant change was detected. These findings are in line 
with a study performed by Ryan and colleagues36, who examined the effects of 
Pycnogenol on different cognitive and biochemical parameters in a healthy elderly 
population (60-85 years old). In this double-blind, placebo-controlled, matched-pair 
study, 101 participants received Pycnogenol (150mg/d) for three months. The 
participants in the Pycnogenol group showed an improved working memory and 
decreased levels of F2-isoprostanes compared to the control group. 
Indeed, Pycnogenol is able to scavenge both hydroxyl radicals and superoxide 
anions37 and increase the activity of superoxide dismutase, gluthathione peroxidase 
and catalase.38 These in vitro effects have been confirmed in healthy subjects, 
treated with Pycnogenol 150 mg QD.39 In that study oxygen radical absorption 
capacity increased by 40% during treatment and returned to baseline after wash-out. 
However, there was no significant change in plasma lipid peroxidation or in LDL-
cholesterol oxidation.39 These data are in line with our study, showing no changes in 
plasma lipids including ox-LDL or in total antioxidative capacity. 
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Endothelial dysfunction has been linked to elevated blood levels of asymmetric 
dimethylarginine (ADMA), which is an endogenous inhibitor of NO synthesis.40, 41 
Even small changes of ADMA concentration alter vascular NO production. Symmetric 
dimethylarginin (SDMA) correlates with renal function and indicates an increased 
cardiovascular risk.42, 43 It has been shown to increase production of ROS and is 
associated with atrial fibrillation, endothelial and platelet activation. Although ADMA 
plasma levels revealed tended to be lower after Pycnogenol treatment neither the 
effect on ADMA nor SDMA concentrations reached statistical significance. Although 
the L-arginine / NO metabolism was not studied in particular, our finding strongly 
suggests that alterations in the L-arginine/NO metabolisms are unlikely involved in 
the endothelial protective effects of Pycnogenol. 
Endothelin-1 (ET-1) is a potent vasoconstrictor modulating the release and action of 
NO in the vessel wall.44 Furthermore, previous studies suggested45 that Pycnogenol 
may lower during the plasma levels of the peptide. However, in the current study no 
statistically significant effect of the flavonoid extract could be observed. This might be 
due to the fact that all participants, although CAD patients, exhibited low ET-1 
plasma levels at the lower limit of the physiological reference range. Thus, it cannot 
be excluded that Pycnogenol might affect vascular ET-1 tissue levels. 
The anti-inflammatory properties of Pycnogenol have been demonstrated in a large 
variety of studies, both in vitro and in vivo.46 Pycnogenol is able to inhibit tumour 
necrosis factor-alpha (TNF-α) induced nuclear factor kappa B (NF-κB) activation and 
adhesion molecule expression in human umbilical vein endothelial cells.47 In two 
double-blind, randomized, placebo-controlled trials in patients with asthma, the 
investigators found improved asthma symptom scores as well as improved 
pulmonary function, which was paralleled by a reduction in plasma, as well as in 
urine leukotriene concentrations after Pycnogenol treatment.48, 49 While we could 
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demonstrate a marked improvement in endothelial function in stable CAD patients 
treated with Pycnogenol for 8 weeks, which was paralleled by a decrease in 15-F2t-
Isoprostane, we could not demonstrate an improvement in inflammatory parameters 
(hs-CRP, sVCAM, sICAM, sCD40L) or total antioxidative capacity. This lack of effect 
may be due to the sample-size, which of course was calculated for the primary 
endpoint. 
The effects of Pycnogenol on platelet function were investigated by Araghi-Niknam et 
al. in 60 patients with stable coronary artery disease (CAD), using the PFA-100 test 
with adenosine diphosphate (ADP) or arachidonic acid (AA) induced platelet 
aggregation.50 After 4 weeks of treatment with the flavonoid extract at a dose of 
450mg/d a significant reduction of platelet aggregation was observed compared to 
placebo or baseline values. However, in our study using Pycnogenol 200mg QD we 
did not found any difference in shear-stress dependent platelet function, which 
suggests that higher dosages of Pycnogenol are needed to inhibit platelet function. 
Recent studies suggested a blood pressure-lowering effect of Pycnogenol. In a 
double-blind, placebo-controlled cross-over study involving 11 patients, 
supplementation with Pycnogenol 200 mg QD significantly reduced systolic blood 
pressure of patients with mild to moderate hypertension from 139.9±3.3 mmHg to 
132.7±4.18 mmHg (p<0.05) after eight weeks of therapy, while diastolic blood 
pressure remained stable (93.8±1.23 vs. 92±1.7 mmHg, p=ns).48 In another double-
blind, placebo-controlled trial randomizing 58 hypertensive subjects, intake of 100 
mg/d Pycnogenol allowed to reduce the dosage of the calcium channel blocker 
nifedipine required to maintain normal blood pressure levels.45 However, we did not 
find any change in systolic or diastolic blood pressure in our study. This may be 
explained, at least in part by the fact, that the blood pressure in our study was well 
controlled at study entry. 
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Conclusion 
This study demonstrates for the first time an improvement of endothelial function 
after 8 weeks treatment with Pycnogenol at a dose of 200 mg QD in patients with 
stable coronary artery disease. As Pycnogenol significantly reduced oxidative stress 
as assessed by plasma levels of 8-isoprostanes, but left ADMA and SDMA as well as 
plasma endothelin-1 levels unaffected, these protective effects may be related to the 
antioxidative properties of the flavonoid extract. The clinical implications of these 
findings need be confirmed in large-scale clinical outcome trials. 
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Legend to the figures 
 
Figure 1: Flow mediated dilatation (FMD, %) of the brachial artery in patients 
receiving Pycnogenol (black bar) or placebo (white bar). * p<0.05 vs. baseline, § 
p<0.05 vs. placebo. 
 
Figure 2: 15-F2t-Isoprostane before and after Pycnogenol (black bar) or placebo 
(white bar); * p<0.05 vs baseline, § p<0.05 vs. placebo. 
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Table 1: Clinical measures before and after 8-weeks treatment with Pycnogenol or 
placebo and concomitant medication. 
 Baseline for 
treatment 
period 
Pycnogenol  Baseline 
for control 
period 
Placebo 
Clinical parameters     
FMD (%) 5.3±2.6 7.0±3.1*# 5.4±2.4 4.7±2.0 
GTN (%) 18.4±5.4 19.4±4.8 19.5±5.4 19.7±5.7 
     
24-hour SBP (mmHg) 125.8±8.7 125.5±8.1 124.8±9.7 125.7±8.1 
24-hour DBP (mmHg) 75.0±7.0 74.3±7.3 73.9±7.5 74.4±6.6 
     
Office SBP (mmHg) 129.9±12.5 131.8±14.5 130.1±12.1 129.8±11.7 
Office DBP (mmHg) 77.4±6.8 78.9±7.7 78.9±7.5 79.7±8.0 
Office HR (bpm) 58.3±8.3 59.4±9.0 60.3±12.3 57.6±9.9 
     
Concomitant 
Medication     
Aspirin 23/23 (100%)    
Statin 20/23 (87%)    
ACE-Inhibitor / ARB 18/23 (78%)    
Betablocker 17/23 (74%)    
Diuretics 8/23 (35%)    
Calcium-Antagonist 4/23 (17%)    
Clopidogrel 4/23 (17%)    
Ezetimibe 4/23 (17%)    
Oral anti-diabetics 4/23 (17%)    
Marcoumar 1/23 (4%)    
Alpha-Antagonist 1/23 (4%)    
* p<0.05 vs baseline, # p<0.05 vs placebo 
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Table 2. Laboratory values before and after treatment with Pycnogenol or placebo. 
 
Baseline before 
treatment period 
Pycnogenol Baseline 
before control 
period 
Placebo 
Hb (g/L) 14.5±1.2 14.5±1.2 14.6±1.2 14.7±1.2 
Hk (%) 41.4±3.2 41.3±3.8 41.1±3.4 41.6±3.3 
Sodium (mmol/L) 141.1±2.3 141.6±2.2 141.4±2.1 141.9±2.1 
Potassium (mmol/L) 3.9±0.3 3.8±0.4 3.9±0.4 3.8±0.4 
Creatinine (µmol/L) 91.7±13.9 90.6±25 91.6±16.7 93.4±14.1 
Glucose (mmol/L) 5.7±1.4 5.6±1.3 5.7±1.1 5.7±1.3 
TC (mmol/L) 4.6±0.6 4.6±0.7 4.7±0.7 4.8±0.8 
HDL-C (mmol/L) 1.4±0.4 1.4±0.4 1.4±0.4 1.4±0.4 
LDL-C (mmol/L) 2.5±0.5 2.5±0.6 2.6±0.6 2.7±0.7 
TG (mmol/L) 1.4±0.7 1.5±0.7 1.5±0.9 1.5±0.9 
ALT (U/L) 27.7±4.9  30.0±7.0 29.4±6.3 29.2±5.4 
AST (U/L) 29.5±8.2 31.6±9.3 92.6±9.7 32.9±9.9 
hs-CRP (mg/l) 1.52±1.37 1.52.±1.33 1.63±1.71 1.91 ± 3.4 
Lp-PLA2 (ng/ml) 315.89±23.5 321±27.7 279.4±20.4 368.6±24.8 
15-F2t-Isoprostane (pg/ml) 0.71±0.09 0.66±0.13*# 0.72±0.09 0.75±0.10 
ADMA (µM) 0.47±0.11 0.49±0.11 0.45±0.12 0.50±0.12 
SDMA (µM) 0.47±0.13 0.47±0.13 0.45±0.12 0.51±0.13 
Endothelin-1 (ng/l) 1.20±0.36 1.27±0.30 1.23±0.27 1.21±0.30 
Platelet Adhesion (%) 3.84±2.0 3.49±1.45 3.2±1.6 3.2±2.0 
Total antioxidant capacity (µM) 10.12±1.65 10.1±1.28 9.65±2.72 9.78±2.70 
sVCAM (ng/mL) 869±232 791±226 824±265 783±244 
sICAM (ng/mL) 284±90 232±77 277±91 274±130 
sCD40L (ng/mL) 0.54±1.11 0.50±1.0 0.54±1.10 0.46±1.01 
OxLDL (ng/mL) 77.9±119.0 78.9±123.5 85.8±155.4 88.5±154.0 
* p<0.05 vs baseline, # p<0.05 vs placebo 
 
 
